Atai’s amended S-1 filing, submitted to the SEC today, reveals a target valuation of around $2.3bn. The Berlin-based biotech, which has a number of programs that focus on psychedelics, hopes to sell approximately 14.3 million shares. Those shares will be priced between $13 and $15 each. Atai’s latest round was a $157m Series D, which it announced the closing of earlier this year.
